When given before or after tumor inoculation, α-GalCer co-formulated with tumor antigens increased overall survival in mice, a protective effect that was largely dependent on enhanced CD4 and CD8 T cell responses [143,144,145]. The gene discussed is CD8A; the disease is neoplasm.